Single-agent vinorelbine in pretreated breast cancer patients: comparison of two different schedules.

E. Terzoli(Catholic University of America), F. Cognetti(Sapienza University of Rome), Emilio Bria(Università Cattolica del Sacro Cuore), Virginia Ferraresi(Cancer Institute (WIA)), Cecilia Nisticò(Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori), Alessandra Fabi(Agostino Gemelli University Polyclinic), Angela Vaccaro(Accademia di Belle Arti di Frosinone), Carlo Garufi(Fondazione IRCCS Istituto Nazionale dei Tumori), Barbara Vanni(Tumori Foundation), Paola Papaldo(Cancer Institute (WIA)), Diana Giannarelli(Agostino Gemelli University Polyclinic), Francesco Izzo(Istituto Nazionale Tumori IRCCS "Fondazione G. Pascale"), Paolo Carlini(National Cancer Institute), A.M. D'Ottavio(Cancer Institute (WIA)), Michèle Milella(National Cancer Institute)
PubMed
June 1, 2004
Cited by 13

Related Papers

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
|The Lancet Oncology|2012|5.5k
Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up
|Annals of Oncology|2018|1.6k
Prolonged Survival in Stage III Melanoma with Ipilimumab Adjuvant Therapy
|New England Journal of Medicine|2016|1.3k
Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
|The Lancet Oncology|2015|1.3k
Soft tissue and visceral sarcomas: ESMO–EURACAN–GENTURIS Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
|Annals of Oncology|2021|978